Stockholm, August 9, 2012 - Karo Bio's CEO, Per Bengtsson, has bought 250 000 Karo Bio shares.
Per Bengtsson, CEO of Karo Bio AB (publ), has bought 250 000 Karo Bio shares. Per Bengtsson's holding totals at 250 000 shares.
For further information, please contact:
CEO Per Bengtsson: cell: +46 734 474 128 or by e-mail: email@example.com
About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas neuropsychiatry, inflammation, autoimmune diseases, cancer and women's health. An important foundation for the company's activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 45 employees and is listed on NASDAQ OMX Stockholm (Reuters: KARO.ST).
Karo Bio publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on August 9, 2012, at 2 pm CET
This press release is also available online at www.karobio.comand www.newsroom.cision.com